What is the difference between Ogivri and Herceptin?

Q: What is the difference between Ogivri and Herceptin?

Ogivri (trastuzumab-dkst) is a biosimilar to Herceptin (trastuzumab). A biosimilar is a biological product that is FDA-approved and highly similar to a biologic already FDA-approved with no clinically meaningful differences in terms of safety and effectiveness from the reference product. What Are Biosimilars? Top Facts You May Not Know Ogivri and Herceptin are both used for the treatment of patients with HER2+ breast cancer or HER2-overexpressing metastatic stomach cancer (metastatic gastric or gastroesophageal junction adenocarcinoma). Ogivri has not been approved as an interchangeable biosimilar, meaning the pharmacist cannot substitute Ogivri for Herceptin without consulting the prescriber. Ogivri was the first approved biosimilar to Herceptin. Herceptin (trastuzumab) Biosimilars Ogivri (trastuzumab-dkst) Herzuma (trastuzumab-pkrb) Ontruzant (trastuzumab-dttb) Trazimera (trastuzumab-qyyp) Kanjinti (trastuzumab-anns)

Medically reviewed by Judith Stewart, BPharm. Last updated on May 16, 2025.

Official Answer by Drugs.com

Ogivri (trastuzumab-dkst) is a biosimilar to Herceptin (trastuzumab).

A biosimilar is a biological product that is FDA-approved and highly similar to a biologic already FDA-approved with no clinically meaningful differences in terms of safety and effectiveness from the reference product.

Ogivri and Herceptin are both used for the treatment of patients with HER2+ breast cancer or HER2-overexpressing metastatic stomach cancer (metastatic gastric or gastroesophageal junction adenocarcinoma).

Ogivri has not been approved as an interchangeable biosimilar, meaning the pharmacist cannot substitute Ogivri for Herceptin without consulting the prescriber.

Ogivri was the first approved biosimilar to Herceptin.

Herceptin (trastuzumab) Biosimilars

Ogivri (trastuzumab-dkst)
Herzuma (trastuzumab-pkrb)
Ontruzant (trastuzumab-dttb)
Trazimera (trastuzumab-qyyp)
Kanjinti (trastuzumab-anns)

What are monoclonal antibodies?

Monoclonal antibodies (mAbs) are man-made proteins that mimic the natural antibodies produced by our immune systems. Monoclonal antibodies can be formulated into medicines to treat various types of illnesses, such as cancer, rheumatoid arthritis or psoriasis.

What are biosimilar drugs and how do they compare to biologics?

A biosimilar is a biological product that is similar to a reference biologic (usually the originally approved product) and for which there are no clinically meaningful differences in terms of safety, purity, and potency. The most recently approved biosimilar is Starjemza (ustekinumab-hmny), an interchangeable biosimilar to Stelara, cleared by the FDA on May 22, 2025.

How soon can you start chemo after port placement?

Chemotherapy can typically begin within a few days to 2 weeks after port placement, depending on factors like healing progress and treatment urgency. While same-day chemotherapy is possible in some cases, most healthcare providers recommend a short waiting period to ensure proper recovery and port functionality.

What is the difference between Ogivri and Herceptin?

Read next

What are monoclonal antibodies?

What are biosimilar drugs and how do they compare to biologics?

How soon can you start chemo after port placement?

See also:

Aimovig

Botox

Trodelvy

Nurtec ODT

Vyepti

Depakote

Topamax

Emgality

Inderal

Ajovy

Related medical questions

Drug information

Related support groups